This activity is expired and is no longer available for CME credit.


Extending the Anti-VEGF Treatment Interval and Its Effect on Visual Outcomes

Author(s)/Faculty: Amy Babiuch , MD; Rishi P. Singh, MD
Release Date: 6/30/2020Expiration Date: 6/29/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: VideoProvider:
Anti-vascular endothelial growth factor (anti-VEGF) therapy has become standard of care for many retinal diseases, such as neovascular age-related macular degeneration and diabetic retinopathy. Clinical trials continue to evaluate intravitreal anti-VEGF therapy in these retinal diseases, further refining treatment protocols, injection intervals, and dosing. Because this new data has the potential to enhance visual acuity gains and/or delay disease progression, it is imperative that these data are taken into consideration when selecting individualized treatment protocols. In this curbside consult, Dr. Rishi Singh and Dr. Amy Babiuch discuss extending the anti-VEGF treatment interval and its effect on visual outcomes for patients with neovascular age-related macular degeneration.